Conditional siRNAs for AML Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current molecularly targeted cancer therapies face limitations in effectively treating cancers like Acute Myeloid Leukemia (AML) due to the heterogeneity of cancer cells and rapid development of drug resistance, as they often target essential genes also vital for normal cells, leading to inefficacy and toxicity.
Innovation Solution
Development of conditional siRNA complexes (Cond-siRNAs) that are inactive in normal cells but activated by biomarkers specific to diseased cells, using a molecular sensor to initiate RNA interference pathways, thereby selectively targeting and inhibiting genes essential for cancer cell survival without affecting normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current molecularly targeted cancer drugs are used to inhibit specific genes essential for cancer cell survival, then cancer cell targeting is improved, but toxicity to normal cells increases because the targeted genes are also vital for normal cell functioning
Solution Approach 1:
The patent applies local quality by designing siRNA molecules with conditionally active structures that have different functional properties in different cellular contexts. The siRNA is structurally modified to be inactive in normal cells but becomes active only in cancer cells expressing specific biomarkers, thereby achieving localized therapeutic effect at the molecular level while preserving normal cell function.
Solution Approach 2:
The patent utilizes parameter changes by modifying the structural and functional parameters of siRNA molecules through conditional activation mechanisms. The siRNA transitions from an inactive state in normal cells to an active state in cancer cells based on the presence of specific biomarkers, changing its functional parameters (such as RNAi activity) in response to cellular conditions.
2Reliability
If molecularly targeted therapies are applied to treat heterogeneous cancer cells, then initial treatment response may be improved, but drug resistance develops rapidly due to cancer cell heterogeneity
Solution Approach 1:
The patent applies universality by designing a platform of multiple conditionally active siRNAs, each targeted at different cancer-relevant genes. This multi-functional approach allows simultaneous targeting of multiple pathways in heterogeneous cancer cell populations, preventing escape through single-pathway resistance and extending treatment durability across diverse cancer subpopulations.
Solution Approach 2:
The patent implements feedback mechanisms through biomarker-dependent conditional activation of siRNAs. The therapeutic effect is automatically regulated by the presence and level of specific cancer biomarkers, creating a feedback loop that maintains effective treatment response while adapting to changes in cancer cell state and preventing resistance development.
3Productivity
If siRNA is designed to be always active for maximum cancer cell killing, then therapeutic efficacy is improved, but off-target effects on normal cells increase
Solution Approach 1:
The patent applies preliminary action by pre-modifying siRNA molecules with conditional activation structures before administration. These structurally modified siRNAs are prepared in an inactive state and only become functional after encountering specific cancer cell biomarkers in vivo, ensuring that cancer cell killing activity is activated only at the target site and not during circulation or in normal tissues.
Solution Approach 2:
The patent uses cancer-specific biomarkers as intermediaries to mediate between the administered siRNA and the RNAi machinery. The biomarkers act as conditional switches that trigger siRNA activation only in cancer cells, serving as an intermediary mechanism that decouples siRNA administration from siRNA activation to prevent off-target effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Cond-siRNAs demonstrate increased specificity and efficacy in targeting cancer cells, reducing toxicity to healthy cells and overcoming drug resistance by activating only in diseased cells, providing a precise therapeutic approach tailored to specific gene expression patterns.
Implementation Method 1
RNA interference (RNAi) is a sequence-specific mRNA degradation pathway mediated by siRNA duplexes
Implementation Method 2
activated by biomarkers specific to diseased cells, using a molecular sensor to initiate RNA interference pathways
Data Source
AI summary
Disclosed herein are conditional siRNAs activatable by CBFβ-MYH11 oncogenic gene and use thereof for treating conditions such as acute myeloid leukemia (AML). The conditional siRNAs target MCL-1 or HDAC8.